Jérémie Mariau

Jérémie Mariau

Company: ILTOO PHARMA

Job title: CEO

Seminars:

Corelates of Biological & Clinical Response to Low-dose Interleukin-2 in Patients with Systemic Lupus Erythematosus: Results from a Phase-II Proof of Concept Trial 4:00 pm

Outline of LUPIL-2, a Phase II Proof of Concept study evaluating ILT-101 in moderate to severe SLE patients Chronic SC administration of ILT-101 is well tolerated ILT-101 treatment clinically improves moderate to severe SLE patients Clinical improvement correlates with Treg stimulation Early Treg activation predicts clinical outcomeRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.